Drug intelligence / Profile preview

SHR-3821

Development stage: Phase 2
Lead developer: Suzhou Suncadia Biopharmaceutical
Administration: Intravenous

Overview

SHR-3821 is an investigational antineoplastic agent developed by Suzhou Suncadia Biopharmaceuticals for the treatment of advanced solid tumors. It is a new molecular entity currently in Phase I clinical trials, administered as an intravenous injection. The precise mechanism of action for SHR-3821 has not been defined or disclosed publicly. Clinical studies are focused on evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with late-stage or advanced solid tumors[1][3][4][7].

Beyond the preview

Go deeper on SHR-3821.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-3821.

Explore the full profile